DEDICATED / HAIR RESEARCH
Copper Peptide Hair Growth and GHK-Cu: What the Studies Show
The single controlled human trial, the angiogenic mechanism, and the important caveat that the trial tested a combination formulation — not pure GHK-Cu.
Copper peptide hair growth: the controlled trial
Copper peptide hair growth claims rest mainly on one controlled human trial. In a 6-month study of 45 men with androgenetic alopecia (Norwood-Hamilton II–V), a complex of 5-aminolevulinic acid and glycyl-histidyl-lysine peptide — marketed as ALAVAX — increased hair count by 52.6 (at 100 mg/mL) and 71.5 (at 50 mg/mL) versus 9.6 for placebo, a statistically significant difference (p < 0.05), with no adverse events in any group [4].
That is the strongest controlled human efficacy signal for a GHK-containing topical, and it is the right place to start any honest copper-peptide-for-hair discussion. It is also where the first caveat lives: the trial tested a 5-ALA + GHK combination, not pure GHK-Cu, so the hair-count gains cannot be assigned to the copper peptide alone.
Does Copper Peptide Regrow Hair? What the Trials Found
Does copper peptide regrow hair? The strongest controlled signal is the ALAVAX trial, where hair-count gains reached 52.6 and 71.5 over six months versus 9.6 for placebo [4]. That is a real, statistically significant result — but it is a single trial of a combination product (5-ALA plus GHK), and the literature has no equivalent large RCT of pure GHK-Cu for hair.
Mechanistically, the case is more developed than the clinical case. GHK-Cu raises VEGF in dermal fibroblasts and supports follicular angiogenesis and matrix turnover [6], and the Wnt/beta-catenin pathway associated with anagen entry is among its documented targets. So the direction of the evidence is favorable; the depth of the controlled human evidence is one combination trial.
The mechanism is angiogenic, not anti-androgen
The most important sourcing distinction for copper-peptide hair claims is mechanism. GHK-Cu is not a DHT blocker. Its follicular activity is attributed to angiogenesis and follicle support — raised VEGF, follicular blood supply, and matrix turnover [6], plus Wnt/beta-catenin signaling associated with driving follicles into the active anagen growth phase.
That makes it mechanistically distinct from 5-alpha-reductase inhibitors, which work by lowering DHT. A copper peptide does not lower androgens; it supports the follicle's environment. For anyone evaluating claims, this matters: 'copper peptide as a natural DHT blocker' is a mechanism the GHK-Cu literature does not support.